Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
24 results
D2.350 - Exploring the Psychological Burden of Hereditary Angioedema Using the Pictorial Representation of Illness and Self Measure (PRISM): Updated Insights from a Prospective Real-Life Cohort
D2.351 - Germline Variant in the GNAI2 Gene Associated with Severe Immune Dysregulation and Autoimmune Hemolytic Anemia in a Pediatric Patient
D2.352 - Epidermodysplasia verruciformis as a sign for STK4 deficiency
D2.353 - Same Disease, Different Clinical Phenotypes: A20 Haploinsufficiency
D2.354 - Evaluation of Subjective Sleep Quality and Psychological Status in Adult Patients with Inborn Errors of Immunity
D2.362 - Clinical and Immunological Characteristics of Non-Infectious Complications in Common Variable Immunodeficiency: A Single-Center Retrospective Evaluation in Adult Patients with CVID
D2.363 - Immunologic Basis of Coexisting Slowly Progressive Insulin-Dependent Diabetes Mellitus (SPIDDM) and Generalized Myasthenia Gravis (MG)
D2.349 - RAPIDe‑3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
D2.357 - Reductions in Hereditary Angioedema Attacks among Patients with C1 Esterase Inhibitor Deficiency who Switched from Another Long-Term Prophylaxis to Berotralstat
D2.360 - Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat
D2.361 - Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat
D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial
D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study
D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis
D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to
D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study
D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download